Protalix BioTherapeutics (PLX)
(Delayed Data from AMEX)
$0.93 USD
-0.11 (-10.58%)
Updated Aug 14, 2024 03:35 PM ET
After-Market: $0.93 0.00 (0.00%) 6:36 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
Protalix BioTherapeutics, Inc. [PLX]
Reports for Purchase
Showing records 1 - 20 ( 77 total )
Company: Protalix BioTherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Elfabrio Approvals Accumulate; 3Q23 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Protalix BioTherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Anticipating Elfabrio Commercial Traction; Raising PT to $10
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Protalix BioTherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Protalix BioTherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
PRX-102 Complete Response Letter Received; Lowering PT to $7
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Protalix BioTherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Final BRIDGE Trial Results Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Protalix BioTherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
PRX-102 Approval Decision Delay; 3Q20 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Protalix BioTherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Pegunigalsidase Expanded Access Program Established; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Protalix BioTherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
PRX-102 Regulatory Submission Accepted; 2Q20 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Protalix BioTherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Alidornase Alfa License Non-Binding Term Sheet From SarcoMed; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Protalix BioTherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
PRX-102 Submission Completion; 1Q20 Financials; Raising PT to $11
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Protalix BioTherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Positive Long-Term BRIDGE Trial Data Released; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Protalix BioTherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Third PRX-102 Phase 3 Trial Completes Enrollment; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Protalix BioTherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2Q19 Financial Results Reported: Moderate Top- and Bottom- Line Miss; Anticipating PRX-102 Filing; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Protalix BioTherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Shine on BRIGHTly; Pivotal Trial Completes Enrollment; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Protalix BioTherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Accelerated Approval Application Planned in Fabry Disease; Estimates Updated; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Protalix BioTherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2018 Financial Results Reported; Revenue Recognition Restatements; Reiterate Buy and Lowering Target to $3
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Protalix BioTherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Preliminary Pivotal Pharmacokinetic Data Shines BRIGHTly; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Protalix BioTherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
PRX-102''s Clinical Development is Chugging Along; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Protalix BioTherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Decreased 2019 Revenue Expectations; Focus on Fabry Disease Pivotal Trials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Protalix BioTherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Positive Preliminary PRX-102 Data Presented at Canadian Symposium; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R